MPS Limited — Investor Meet, 25-05-2026: Analysts/Institutional Investor Meet/Con. Call Updates

MPS Limited reported a record FY26 with 236 Cr EBITDA (+11.8%) and 173 Cr PAT (+16.3%), propelled by a strong Q4. Management projects FY27 EBITDA to comfortably exceed 300 Cr, based on current operating plans. The company's strategic focus is on "AI-first knowledge solutions," emphasizing areas where "AI cannot afford to be wrong" across research, education, and corporate learning. The Unbound Medicine acquisition has diversified its customer base. An active M&A pipeline is influencing capital allocation decisions, with the FY28 top-line target of 1,500 Cr confirmed as intact.